Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-drive ...

Summary of Zentalis Pharmaceuticals Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - **Focus**: Development of azenosertib, a Wee1 inhibitor targeting platinum-resistant ovarian cancer patients with high cyclin E1 expression [4][5] Key Developments - **Current Trials**: - Enrolling in the DENALI Part 2 trial, aimed at accelerated approval [4] - Completed enrollment in the first portion of DENALI trial, comparing 300 mg and 400 mg doses [5] - Initiating Phase 3 confirmatory study named ASPENOVA to support accelerated approval [5][62] Clinical Context - **Standard of Care for Platinum-Resistant Ovarian Cancer (PROC)**: - Current treatments yield response rates of 4%-13% with minimal progression-free survival (PFS) benefits [10] - Notable competitor, mirvetuximab, shows response rates around 30% with a duration of response of 5-6 months [11] Clinical Data and Expectations - **Response Rates**: - Zentalis aims for an overall response rate (ORR) of about 30% or higher, with a duration of response between 5-6 months [14][51] - Historical data from DENALI Part 1b shows a response rate in the low 30s% for cyclin E1 positive patients [20] - **Patient Population**: - Focus on patients with 1-3 prior lines of therapy, specifically those with cyclin E1 high expression [32] Trial Design and Regulatory Strategy - **ASPENOVA Trial**: - Randomized controlled trial designed to gather data on cyclin E1 patients against current standard care [66] - Adaptive design allows for early initiation and flexibility based on DENALI trial outcomes [63][66] - **Sample Size**: - ASPENOVA aims to enroll 420-450 patients [78] Future Directions - **MIRROR Study**: - Planned trial to explore combinations of azenosertib with bevacizumab in earlier lines of therapy for patients who progressed on PARP inhibitors [82][84] - Targeting a second-line maintenance setting with broad eligibility criteria [84] Market Position and Competitive Landscape - **Unmet Need**: - High unmet need in the PROC population, particularly for cyclin E1 high expression patients [10] - Zentalis positions azenosertib as a potential first-in-class treatment for this specific patient group [56] Additional Insights - **Regulatory Considerations**: - The FDA's evolving stance on accelerated approvals may allow for more flexibility in trial enrollment and data requirements [71][77] - **Patient Characteristics**: - The trial will include a mix of HRD positive and negative patients, with a focus on those who have progressed on prior therapies [86][88] This summary encapsulates the key points discussed during the conference call, highlighting Zentalis Pharmaceuticals' strategic focus, clinical developments, and market positioning in the oncology space.

Summary of Zentalis Pharmaceuticals FY Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM: ZNTL) - **Focus**: Development of Azenosertib for Platinum-Resistant Ovarian Cancer (PROC) patients, particularly those with high Cyclin E1 protein expression Key Points and Arguments 1. Strategic Focus and Milestones - 2026 is positioned as a year of momentum for Zentalis, with a focus on Azenosertib in PROC patients with high Cyclin E1 expression [4][5] - Enrollment in the DENALI trial has been completed for Part 2A, with a key readout expected by the end of 2026 [5][6] - A Phase 3 confirmatory trial named ASPENOVA is set to begin enrollment in the first half of 2026 [6][18] 2. Clinical Data and Efficacy - Azenosertib is described as a potential best-in-class oral therapy for patients with high Cyclin E1 expression, which correlates with poorer prognosis [6][7] - Current standard chemotherapy response rates in PROC are low, ranging from 4% to 13%, with Azenosertib showing a response rate of 31%-35% in CCNE positive PROC patients [7][28] - The median duration of response for Azenosertib is reported to be between 4.2 to 6.3 months [28] 3. Patient Population and Market Opportunity - Approximately 21,500 patients in the U.S., EU4, and the U.K. are estimated to have Cyclin E1 expression levels that may benefit from Azenosertib [10][61] - There is a significant unmet need in the PROC population, particularly for patients with Cyclin E1 overexpression, as they currently lack approved therapies [11][12] 4. Safety and Tolerability - Azenosertib has a manageable safety profile, comparable to other cytotoxic agents, with low incidence of high-grade toxicities [13][50] - The company has implemented supportive care measures to help manage tolerability and educate physicians and patients [50][52] 5. Regulatory Pathway and Future Trials - The DENALI Part 2 trial is designed for potential registration for accelerated approval, supported by the ASPENOVA trial [21][58] - The primary endpoint for ASPENOVA will be progression-free survival (PFS), with secondary endpoints including overall survival (OS) and overall response rate (ORR) [20][58] 6. Competitive Landscape - Azenosertib is positioned as a unique oral option compared to other therapies, which often require infusion and can lead to significant time spent in treatment settings [30][32] - The company acknowledges the development of other antibody-drug conjugates (ADCs) but emphasizes the importance of Azenosertib's oral administration and its role in providing a treatment option for patients who have exhausted other therapies [30][32] Additional Important Insights - The company is exploring the combination of Azenosertib with other treatments, such as bevacizumab, in earlier lines of ovarian cancer [21][22] - The ongoing discussions with regulatory agencies indicate a proactive approach to ensure alignment on trial designs and approval pathways [17][58] This summary encapsulates the critical aspects of Zentalis Pharmaceuticals' conference call, highlighting the company's strategic direction, clinical data, market potential, and regulatory considerations.

Summary of Zentalis Pharmaceuticals FY Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - **Focus**: Development of azenosertib, an oral non-chemotherapy treatment for biomarker-selected cancer patients Key Points Clinical Data and Treatment Efficacy - Azenosertib has shown a response rate over 30% and a duration of response of approximately 6 months in clinical trials, which is significantly better than single-agent chemotherapy with low double-digit response rates and short duration [2][3] - Over 500 patients have been treated with azenosertib, either as a monotherapy or in combination, demonstrating clear activity in patients who have failed other treatment options [4] - The DENALI trial is a multi-stage clinical program aimed at potential accelerated approval for azenosertib in PROTAC Cyclin E1-positive patients, with enrollment ongoing and expected to complete by year-end [5][6] Regulatory Pathway and FDA Interaction - The FDA has provided guidance on the accelerated approval pathway, emphasizing the need for a confirmatory randomized trial alongside the DENALI trial [9][10] - The ASPENOVA trial, a Phase 3 confirmatory study against single-agent chemotherapy, is designed to support full approval in the same patient population [5][6] Competitive Landscape - There is increasing competition in the market, particularly from antibody-drug conjugates (ADCs) targeting Folate receptor alpha, which may work regardless of biomarkers [7] - Azenosertib is positioned as a non-chemotherapy option that offers convenience and improved quality of life for patients, as it is an oral treatment compared to traditional IV chemotherapy [11][13] Biomarker Significance - Cyclin E1 overexpression is being studied as a biomarker for patient selection, with both gene amplification and high protein expression correlating to treatment response [29][30] - The DENALI trial includes prospective screening to validate the biomarker, with a focus on ensuring that patients who could benefit are not missed [34] Safety and Tolerability - Azenosertib is considered to have a manageable and well-tolerated safety profile compared to alternatives, with low discontinuation rates due to adverse events [46][48] - The trial management approach has been refined to enhance patient safety and support, which is expected to improve outcomes [39][40] Future Expectations - The company anticipates that the data from the ongoing trials will support the efficacy and safety of azenosertib, potentially leading to improved outcomes compared to previous trials [35][39] - The ASPENOVA trial design is similar to the successful MIRASOL trial, with an adaptive dose randomization to accelerate the process [50] Conclusion - Zentalis Pharmaceuticals is positioned for a pivotal year with the ongoing trials of azenosertib, which could provide a significant advancement in treatment options for patients with specific cancer biomarkers, while also addressing the need for more convenient and less toxic therapies [54]

Summary of Zentalis Pharmaceuticals Conference Call Company Overview - **Company**: Zentalis Pharmaceuticals (NasdaqGM:ZNTL) - **Focus**: Development of azenosertib for platinum-resistant ovarian cancer patients with high Cyclin E1 expression Key Strategic Priorities - **Primary Goal**: Accelerate the development of azenosertib, focusing on patients with platinum-resistant ovarian cancer and high Cyclin E1 expression [4][6] - **Current Trials**: - **DENALI Trial**: Multi-part registration trial, currently in Part 2A with 60 patients enrolled [12][13] - **ASPENOVA Trial**: Phase 3 randomized trial expected to enroll patients in the first half of the year [4][13] Competitive Landscape - **Market Dynamics**: Increasing competition in the platinum-resistant ovarian cancer space, particularly from antibody-drug conjugates (ADCs) [5] - **Differentiation of Azenosertib**: - Oral administration versus infusion for ADCs - Non-chemotherapy option providing a "chemo break" for patients [6][7] Clinical Profile and Tolerability - **Tolerability Data**: - Azenosertib shows a manageable tolerability profile with 10% high-grade neutropenia and low-grade gastrointestinal adverse events [10][11] - Comparison with other WEE1 inhibitors indicates a favorable safety profile [9][10] - **Dose Selection**: - Ongoing evaluation of 300 mg and 400 mg doses in DENALI, with a decision expected in the first half of the year [12][13][17] Biomarker and Patient Selection - **Cyclin E1 Expression**: Approximately 50% of patients in the PROC population are expected to meet the eligibility criteria based on Cyclin E1 expression [27] - **Eligibility Changes**: Part 2 of DENALI has stricter eligibility criteria compared to Part 1, focusing on patients with fewer prior lines of treatment [22] Regulatory Considerations - **Accelerated Approval Metrics**: - Expected overall response rate (ORR) of around 30% and median duration of response of 5-6 months for accelerated approval [48][49] - **ASPENOVA Design**: Randomized controlled trial against standard-of-care, with a focus on the same patient population as DENALI [31][39] Future Opportunities - **Combination Therapies**: Potential for azenosertib to be used in combination with other therapies, including cytotoxic agents and ADCs [50] - **Long-term Strategy**: Zentalis may explore additional assets post-azenosertib, contingent on successful proof of concept [58] Other Important Insights - **USC Study**: Fully enrolled with plans to provide data, but not a top priority for the company [51][56] - **Market Positioning**: Zentalis aims to prioritize ovarian cancer indications while keeping options open for future developments [58]

Core Insights - Zentalis Pharmaceuticals is advancing the late-stage development of its first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment for ovarian cancer [1][3] - The management team will participate in a fireside discussion at Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11 in New York [1] Company Overview - Zentalis Pharmaceuticals focuses on developing innovative oncology treatments, particularly for ovarian cancer and various tumor types [3] - The company aims to provide a targeted, non-chemotherapy, orally available medicine that enhances treatment experience and outcomes for cancer patients [3] Event Information - A live webcast of the upcoming event will be available for at least 30 days after the event concludes, accessible under the "Events & Presentations" tab on the company's website [2]

Group 1: Market Activity - Several biotech and healthcare companies experienced notable gains in after-hours trading, indicating renewed investor interest in drug development and healthcare services [1] - Zentalis Pharmaceuticals, Inc. (ZNTL) surged 17.65% to close at $4.40, attributed to a recent corporate update that boosted investor confidence in its azenosertib development program [2] - LifeMD, Inc. (LFMD) climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability [3] Group 2: Company-Specific Developments - NanoViricides, Inc. (NNVC) advanced 11.11% to $1.24, driven by speculative interest despite no recent news [4] - Intelligent Bio Solutions Inc. (INBS) posted a 9.10% increase, closing at $19.55, continuing to gain momentum from overall investor enthusiasm in the biotech sector [4] - IO Biotech, Inc. (IOBT) rose 6.49% to $0.60, suggesting bargain-hunting activity at lower price levels [5] Group 3: Financing and Agreements - China SXT Pharmaceuticals, Inc. (SXTC) advanced 2.06% to $18.29 after disclosing a definitive agreement for the purchase of 66,666,666 Class A ordinary shares at $0.15 per share, highlighting efforts to strengthen its capital position [6]

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading, driven by corporate updates, clinical milestones, and acquisition speculation [1] Company Updates - China SXT Pharmaceuticals, Inc. (SXTC) saw a 13.6% increase to $1.42, following the announcement of its Strategic Artificial Intelligence Insights Initiative aimed at integrating AI-driven analytics into product planning and market intelligence [2] - Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65 after reports of Merck's acquisition talks and the FDA granting Breakthrough Therapy Designation to its drug zoldonrasib for treating specific lung cancer patients [3] - KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04 after reporting preliminary unaudited global net product revenue results for Q4 and the full year ended December 31, 2025, along with other operational indicators [4] - Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, likely due to investor reactions to a previous corporate update outlining key milestones for its drug azenosertib [5] - BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81 without new announcements, indicating momentum-driven trading [6] - Sagimet Biosciences Inc. (SGMT) increased 7.7% to $6.00 after announcing plans to present clinical trial results at an upcoming conference, highlighting anti-fibrotic effects observed in patients [7]

Core Insights - Zentalis Pharmaceuticals is advancing the development of azenosertib, a first-in-class WEE1 inhibitor, targeting Cyclin E1-positive platinum-resistant ovarian cancer (PROC) with significant unmet medical needs [2][8] Company Updates - The completion of enrollment in DENALI Part 2a is a significant milestone, with dose confirmation expected in the first half of 2026 and a topline readout anticipated by the end of 2026, which could support accelerated approval from the FDA [2][6] - The initiation of the ASPENOVA Phase 3 trial is planned for the first half of 2026, comparing azenosertib to standard-of-care chemotherapy in a biomarker-selected population [2][5] - Zentalis maintains a strong financial position with cash, cash equivalents, and marketable securities totaling $280.7 million as of September 30, 2025, providing a runway into late 2027 [3][6] Clinical Development - Azenosertib is being evaluated in clinical studies for ovarian cancer and other tumor types, with a focus on its role in earlier lines of ovarian cancer and additional indications [2][5] - The DENALI clinical trial is designed for accelerated approval, with Part 2 focusing on patients with Cyclin E1 protein overexpression, which is a predictive biomarker for treatment benefit [9][8] - Strong data from three trials in PROC have established a solid foundation for azenosertib as a lead indication, demonstrating clinically meaningful results and a manageable safety profile [6][9]

Core Insights - Zentalis Pharmaceuticals (ZNTL) is a microcap biotech company focused on developing targeted therapies for DNA damage repair [1] - The company has undergone a recent restructuring and is now concentrating all efforts on the late-stage development of a single drug [1] Company Overview - Zentalis Pharmaceuticals specializes in targeted therapies within the DNA damage repair sector [1] - The company is currently in a pivotal phase, emphasizing the late-stage development of one specific drug following a strategic restructuring [1]